胃转安方治疗胃癌前病变患者临床观察及胃蛋白酶原(PG)的影响  

Pepsinogen Effect of Weizhuan'an Treatment of Patients with PLGC

作　　者：杨阔[1] 刘华一[1] 王秀娟[1] 杜闻媛[1] 李桂珍[1] 赵俊芳[1] 张莎[2] 于磊[3] 

机构地区：[1]天津市中医药研究院附属医院,天津300120 [2]天津市和平区中医医院,天津300050 [3]天津中医药大学,天津300193

出　　处：《中华中医药学刊》2016年第10期2464-2467,共4页Chinese Archives of Traditional Chinese Medicine

基　　金：天津市卫生局科技基金重点项目(13KG137)

摘　　要：目的:临床观察中医药胃转安一、二号冲剂对胃癌前病变患者的治疗效果及对胃蛋白酶原的影响。方法:诊于天津市中医药研究院附属医院的胃癌前病变患者共96名。将其随机分成治疗组和对照组,每组48例。治疗组根据中医辨证为气虚夹瘀毒型(32例)及阴虚夹瘀毒型(16例),分别给予院内制剂胃转安一号冲剂及胃转安二号冲剂;对照组给予胃复春片。3个月为1个疗程,连续观察2个疗程。记录并观察两组治疗前后临床症状、体征、中医证侯评分及胃镜、病理及血清胃蛋白酶原表达的情况。数据采用SPSS 19.0统计软件进行统计分析。结果:治疗组经过治疗后,患者在胃脘疼痛、痞闷胀满、嗳气吞酸、纳呆食少、嘈杂、肢体倦怠、神疲懒言、咽干口苦、潮热盗汗方面及胃镜总评分、病理萎缩程度评分、肠上皮化生评分及异性增生评分上,较治疗前均有明显改善,结果显示具有统计学差异(P<0.05)。治疗后两组比较,在胃脘疼痛、痞闷胀满、嘈杂、肢体倦怠、神疲懒言、潮热盗汗及肠上皮化生、异型增生评分方面,治疗组优于对照组,具有统计学差异(P<0.05)。临床综合疗效、胃镜疗效、病理疗效,治疗组均优于对照组。血清PG I、PGR水平治疗后较治疗前均有提高(P<0.05),且治疗组血清PG I改善情况明显优于对照组(P<0.05)。结论:胃转安一、二方对胃癌前病变患者有明显疗效,值得进一步研究及临床推广。Objective： To evaluate the pepsinogen effect of Weizhuanan treatment of patients with PLGC. Methods： Confirmed by gastroscopy pathological examination in Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital,a total of 96 cases were randomly divided into treatment group and control group, each group 48 cases. Treatment group according to syndrome differentiation was divided into Qixuyudu group （32 cases） and Yinxuyudu group （16 cases）, re- spectively treated with Traditional Chinese Medicine Weizhuanan 1 and Weizhuanan 2,1 bag for each time,3 times a day. Control group treatment for Chinese patent medicine Weifuchun,4 tablets for each time,3 times a day. Three months was one course of treatment and there were two continuous two courses of treatment. Record and observe groups＇ clinical symptoms,TCM syndrome and gastroscope and pathology and PG score before and after treatment, using SPSS19.0 statisti- cal software to do the statistical analysis. Results ： After treatment, treatment group＇ s clinical symptoms, TCM syndrome and gastroscope and pathology score were obviously improved with statistically difference （ P 〈 0.05 ）. Treatment group was better than control group on stomach pain, distention and fullness, noisy, lassitude, tired and silence, tidal fever and night sweating and intestinal metaplasia or dysplasia score, with statistical difference （ P 〈 0.05 ）. Treatment group was better than control group on the comprehensive clinical efficacy and endoscopy efficacy and clinical pathology efficacy.Treatment group＇ s PG I and PGR were obviously improved. Treatment group was better than control group on PG I （P 〈 0. 05 ）. Conclusions ： Weizhuanan 1 and Weizhuanan 2 have obvious curative effect in patients with PLGC, deserving further research and clinical promotion.

关 键 词：胃癌前病变 中医药 胃蛋白酶原 胃转安一号 胃转安二号 

分 类 号：R735.2[医药卫生—肿瘤]